Height-age as an alternative growth outcome

Height-age as an alternative to height-for-age z-scores to assess the effect of interventions on child linear growth in low- and middle-income countries

Kelly M Watson^{1,2}, Alison SB Dasiewicz¹, Diego G Bassani^{1,3}, Chun-Yuan Chen¹, Huma Qamar¹, Karen M O'Callaghan^{1,4}, Daniel E Roth^{1,2,3}

¹ Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada

² Department of Nutritional Sciences, University of Toronto, Toronto, Canada

³ Department of Paediatrics, University of Toronto, Toronto, Canada

⁴ Department of Nutritional Sciences, King's College London, London, UK

Corresponding Author:

Daniel Roth Centre for Global Child Health The Hospital for Sick Children 686 Bay St, Toronto, ON M5G 0A4, Canada Tel: 416-813-7654 ext. 328807 Email: daniel.roth@sickkids.ca

Sources of Support: Kelly Watson was funded by the Canadian Institutes of Health Research (CIHR), through the Canadian Graduate Scholarship – Masters (CGS-M) and a project grant (#169133). The CIHR had no involvement in this study and does not restrict works for publication.

Abbreviations:

BONUSKids. BONe and mUScle health in Kids CI, confidence interval DIVIDS, Delhi Infant Vitamin D Supplementation HAZ, height-for-age z-score IPD, individual participant data LAZ, length-for-age z-score LMICs, low- and middle-income countries LMS, lambda-mu-sigma MD, mean difference MDIG, Maternal vitamin D for Infant Growth PMB, proportion of maximal benefit RCT, randomized controlled trial REB. research ethics board SD, standard deviation SE. standard error SickKids, The Hospital for Sick Children WHO-GS, WHO growth standards

Height-age as an alternative growth outcome

1 Abstract

Background: Assessments of the efficacy of interventions to improve child growth are
often based on differences in mean height-for-age z-scores (HAZ) and stunting (HAZ<-
2) in randomized controlled trials (RCTs). However, this approach does not account for
children's starting skeletal age and does not enable assessment of the extent to which
interventions optimized linear growth.

7 **Objective**: To develop and apply a new method using height-age to express linear

8 growth effects in RCTs.

9 **Methods**: Longitudinal individual participant data (IPD) from a Bangladeshi trial cohort

10 were used to compare height-age estimates derived from individual-level heights, mean

11 raw height, or mean HAZ. Then, using average height-age as a proxy for skeletal age,

12 we developed the 'proportion of maximal benefit' (PMB) metric to quantify intervention

13 effects relative to optimal growth for children's starting skeletal age. Optimal growth

14 occurs when height-age increases in parallel with chronological age (i.e., PMB=100%)

whereas no effect (versus control) corresponds to a PMB of 0%. Linear growth

16 outcomes in 4 published RCTs of nutrition-specific interventions were re-expressed as

17 mean height-age and PMB, and compared to effects conventionally expressed as

18 intervention-versus-control mean differences (MD) in HAZ.

Results: Mean height-age could be derived from any published estimate of mean raw height or mean HAZ; however, to calculate the PMB, height or HAZ data were required at both the beginning and end of the observation period. Interpretations of intervention effects were consistent when expressed as either the height-age MD or HAZ MD. In

Height-age as an alternative growth outcome

- 23 contrast, the PMB does not have a corresponding metric on the HAZ scale, and
- therefore provided a new way to quantify intervention efficacy.
- 25 **Conclusion**: Height-age can be used as an alternative to HAZ to express intervention
- 26 effects. The PMB has the advantage of conveying the extent to which an intervention
- improved average linear growth in relation to a biologically-defined benchmark.
- 28 Keywords: Stunting; Low and Middle Income Countries; child growth; height-for-age Z-
- 29 scores; height-age

Height-age as an alternative growth outcome

30 INTRODUCTION

Child height is a general marker of health and nutritional status and is commonly used 31 as an outcome in interventional trials and evaluations of programs aimed at reducing 32 33 undernutrition in low- and middle-income countries (LMICs) (1, 2). Sex- and agestandardized height-for-age z-scores (HAZ) and stunting (HAZ<-2) relative to the WHO 34 35 Growth Standards (WHO-GS) are conventionally used to quantify growth deficits in 36 individuals and populations (3). Candidate interventions to improve child health and 37 nutrition are often considered for adoption as public health programs in LMICs based on 38 the extent to which they increase mean HAZ and reduce stunting prevalence in randomized controlled trials (RCTs). However, the conventional reliance on HAZ and 39 40 stunting to assess changes in child health and nutritional status have been guestioned (4-8). One limitation is that the use of stunting may lead to a disproportionate focus on 41 the sub-group of children classified as stunted, even though linear growth faltering 42 43 affects the entire height-for-age distribution in LMICs (5, 6). Another concern is that it is unrealistic to expect a large change in HAZ or stunting in response to a single, short-44 term intervention given that the cause of linear growth faltering is multi-factorial, leading 45 46 to interventions being perceived as failures even if they are shown to have other health or social benefits (4, 8). Additionally, the use of HAZ (or raw height) in linear growth 47 48 outcome analyses does not enable definition of a population's maximum biologically 49 plausible growth that could occur over an observation period, so there is no objective benchmark to evaluate the adequacy of a response to an intervention using the HAZ or 50 51 raw height scale.

Height-age as an alternative growth outcome

53	Height-age, defined as the age at which the observed height of children would be
54	considered normal, is an alternative way of expressing linear growth that conveys
55	information about the stage of maturation of long bones ('skeletal age'). Skeletal
56	maturation is driven by mechanisms intrinsic to the growth plate, such that skeletal age
57	and chronological age become uncoupled (skeletal age < chronological age) under
58	growth-inhibiting conditions (e.g., nutritional deficiencies) (9-11). Following remediation
59	of the causes of growth impairments, linear growth has been observed to proceed at a
60	rate expected for the younger skeletal age (or height-age), rather than chronological
61	age (9, 12-15).

62

Setting expectations for successful interventions based on HAZ and stunting, which are 63 64 normalized relative to expected growth for children's chronological age, may contribute to the perception that candidate interventions often fail to improve linear growth (4, 8). 65 The aim of the present methodological study was to develop metrics to use height-age 66 as an alternative outcome to stunting and HAZ in RCT analysis and to demonstrate 67 these metrics in a pilot study to enable their wider application and further validation in 68 69 future research. As this was a novel application of height-age, we first compared 70 different ways of deriving height-age estimates using RCT datasets, which enabled us 71 to propose a preferred method for future uses. We also developed a new metric based 72 on height-age that quantifies the extent of linear growth improvement achieved by interventions on the height-age scale. 73

74

Height-age as an alternative growth outcome

75 METHODS

- 76 Data sources
- 77 Individual participant data (IPD) from the Maternal Vitamin D for Infant Growth (MDIG)
- trial (16) and follow-up BONe and mUScle health in Kids (BONUSKids) study in Dhaka,
- 79 Bangladesh (17) were used to compare height-age estimates generated from different
- 80 expressions of height data. Briefly, the MDIG trial was a randomized, placebo-
- 81 controlled, dose-ranging trial of maternal vitamin D supplementation during pregnancy
- and lactation. One group received neither prenatal or postpartum vitamin D (placebo
- group); three groups received prenatal supplementation only (4200 IU, 16,800 IU, or
- 84 28,000 IU per week); one group received prenatal and postpartum supplementation up
- to 26-weeks (28,000 IU per week; denoted as '28000:28000 IU' which corresponds to
- 6 'prenatal:postpartum'). The MDIG trial assessed linear growth in children from birth to
- 87 24 months of age, and the BONUSKids follow-up study assessed the MDIG trial cohort
- at 4 years of age. Ethical approval was obtained from The Hospital for Sick Children's
- 89 (SickKids) research ethics board (REB) for use of MDIG and BONUSKids IPD in this
- study (SickKids REB #1000079659). Published estimates from selected intervention
- 91 trials (18-22) based on inclusion criteria (outlined below) were used in a pilot application
- 92 of novel height-age-based methods.
- 93

94 Existing height-age derivation methods

Height-age was defined as the age at which the WHO-GS median length or height
equaled children's observed mean length or height (hereafter, "height" will refer to
measures of length or height). The WHO-GS height-for-age curves, which include the

Height-age as an alternative growth outcome

98 median growth trajectory, are generated by the lamda-mu-sigma (LMS) method (23), using the publicly available WHO-LMS table containing the data underlying the WHO-99 100 GS curves ('lenanthro.dta' file) (24). The relevant parameters from the WHO-GS LMS 101 table for calculating height-age were the median height (cm), and the corresponding 102 age (in days) and sex (male/female). Height-age is the age corresponding to the median 103 height in the WHO-GS LMS table closest to the observed mean height. If group-level 104 mean HAZ was the only estimate available in the published literature (e.g., only mean 105 HAZ, not mean height, was reported), the observed mean height was back-calculated 106 from the reported mean HAZ. Equation 1 was rearranged to solve for 'y' (the observed 107 height) (3). The median height (M) and coefficient of variation (S), corresponding to the 108 average age of children at the time (t) mean HAZ was measured, were selected from 109 the WHO-LMS table to facilitate this calculation. The power (L) in the WHO-LMS table is 110 always equal to 1 (24).

111 Equation 1:
$$Z_{ind} = \frac{\left[\frac{y}{M(t)}\right]^{L(t)} - 1}{S(t)L(t)}$$

112

The Supplementary Data file from Mansukoski *et al.* includes publicly available code to
derive height-age from mean HAZ (25).

I (+)

115

116 Extension of height-age derivation methods

We considered mean height (rather than individual-level height or mean HAZ) to be the preferred expression of height data for deriving height-age, since the expectation that growth tracks along the median trajectory is applicable at the population level but not for individual children, and mean height can be directly compared to the WHO-GS median

Height-age as an alternative growth outcome

(avoiding the back-calculation required for HAZ). Building on prior work, we documented
a method to derive height-age from mean height when data is disaggregated by sex, or
combining sexes using a sex-weighted or simple average of the WHO-GS LMS table
parameters (26).

125

126 We developed a new workflow for calculating height-age when children were measured 127 at or near two years of age (Figure 1). At this age, there is typically a switch from 128 measuring supine (recumbent) length to standing height which leads to a slight 129 reduction in measured stature (~0.7cm) (27). The WHO-LMS table presents the median 130 as recumbent length when age is <731 days (2 years) and standing height when age is 131 >=731 days (24). The WHO macro for calculating z-scores converts height 132 measurements to length for children under 2 years of age (by adding 0.7cm), or length 133 to height for children >=2 years (by subtracting 0.7cm) (28). Figure 1 shows how we 134 adjusted the WHO median values presented in the LMS table to ensure fair comparison 135 with observed measurements when determining height-age. For example, if using an 136 observed mean height measurement of 2-year-old children who have experienced prior 137 linear growth faltering to calculate height-age, it can be assumed that their calculated 138 average height-age will be *less* than 2 years. It is then necessary to convert WHO-GS 139 median values for children <2 years of age (which typically represent supine length 140 measurements) to standing height measurements, by subtracting 0.7cm from all 141 medians representing supine length measurements. This ensures the observed height 142 is compared with a median value reflecting a standing height measurement. 143

Height-age as an alternative growth outcome

144 Development of the proportion of maximal benefit (the 'PMB') metric

The 'proportion of maximal benefit' (PMB) was developed to quantify the extent to which 145 146 children in an intervention group reached a theoretical benchmark of optimal growth. 147 defined as the normal growth rate for their baseline height-age. The normal ('optimal') 148 growth rate for children's average starting height-age was defined by the median 149 trajectory of the WHO-GS height-for-age chart; however, as the expected growth rate 150 constantly changes on the height-for-age scale (Figure 2 Panel A), the median 151 trajectory was converted to a plot of *height-age*-for-age, by changing the y-axis from 152 height (cm) to height-age (days) (Figure 2 Panel B). On this new scale, the normal growth rate is achieved when height-age increases the same amount as chronological 153 154 age (slope = 1), and in contrast to the height-for-age curve, this relationship is constant 155 across age (straight-line function).

156

157 Using this simple 1-to-1 expected relationship between height-age and chronological 158 age, the theoretical maximum growth potential of children in the intervention group can 159 be defined by the group's change in chronological age during the observation period 160 (ΔCA_i) . The observed effect of the intervention, expressed as the intervention group's 161 change in height-age during the observation period (ΔHA_{l}), can be compared to this 162 benchmark. The control group's change in height-age during the observation period 163 (ΔHA_c) was used as the lower bound, as it was assumed that if the intervention 164 provided no benefit at all, growth in the intervention group(s) would proceed at the same 165 rate as in the control group. All changes (Δs) were measured over the same observation

Height-age as an alternative growth outcome

166 period, expressed in the same units of time (days, months, etc.), and input into Equation

167 2 to calculate the PMB.

168 Equation 2:
$$PMB = \frac{\Delta HA_I - \Delta HA_C}{\Delta CA_I - \Delta HA_C} * 100\%$$

169

A PMB of 0% means that the change in height-age was equal in the intervention and 170 control groups during the intervention period, implying that the intervention had no 171 172 effect. A PMB of 100% means that height-age in the intervention group increased at the 173 same rate as chronological age, which implies achievement of the optimal growth rate 174 (Figure 2). While achieving 100% is mathematically possible, it is expected that the PMB resulting from a single, short-term intervention that addresses only a fraction of the 175 176 factors inhibiting linear growth will be much lower than 100%. Therefore, achieving a 177 PMB of 100% should not be considered a realistic target for successful interventions in 178 such settings; however, further use of the PMB for a variety of interventions will be 179 required to establish specific PMB thresholds for policy-relevant applications. 180 Application of height-age and the PMB in a pilot study 181 182 i) Inclusion criteria Inclusion criteria for intervention trials included in this pilot study were: 1) RCT or a 183

184 follow-up report of a previously conducted RCT; 2) conducted in a low, lower-middle, or

- 185 upper-middle income country as defined by the World Bank classifications (29); 3) study
- 186 population was infants or young children (between 0 to 5 years of age); 4) intervention

Height-age as an alternative growth outcome

187 was nutrition-specific (e.g., vitamin D supplementation); 5) study or group-level HAZ at
188 baseline and end-line of the intervention period were available.

189

190 The MDIG trial and BONUSKids study were also included and summary estimates were 191 generated to emulate having access to study or group-level data only, as was the case 192 with the other studies included. As well, for comparability with another vitamin D 193 supplementation trial included, only the 28000:28000 IU/week maternal vitamin D 194 supplementation group was included (the only group with postpartum supplementation), 195 the intervention period was defined as 0 to 6 months of age (the time post-delivery in 196 which the maternal intervention was ongoing), and the post-intervention period as 6 to 197 48 months.

198

199 ii) Preliminary steps

200 To re-express trial outcomes, mean HAZ was used to derive mean height-age as it was 201 more commonly reported than mean height and thereby enabled a more consistent 202 approach across included trials. As mean height was a priori defined as the preferred 203 method for deriving mean height-age, we compared height-age estimates (means and 204 95% CIs) derived from mean HAZ to corresponding estimates derived from mean height 205 or individual-level heights. The purpose of this preliminary step was to ensure mean 206 HAZ-derived height-age estimates in the pilot study were similar to estimates derived 207 from preferred methods. Individual-level child data (age, sex, length or height) from the 208 MDIG trial and BONUSKids study at the 3, 6, 9, 12, 24, and 48 months encounters were 209 used to generate these height-age estimates from the different expressions of height

Height-age as an alternative growth outcome

210	data (Figure 3). Differences between mean height-age estimates derived from mean
211	HAZ versus mean height, and height-age standard errors (SEs) derived from mean HAZ
212	versus individual-level heights were calculated. The mean, median, standard deviation
213	(SD), kurtosis, and skewness generated from kernel density plots of individual-level
214	height, HAZ, and height-age were also compared at the selected timepoints using MDIG
215	and BONUSKids data to identify any statistical differences of the height-age distribution
216	that may influence interpretation.
217	
218	iii) Data extraction from included trials in the pilot study
219	Mean HAZ reported at baseline and end-line were extracted from published reports of
220	included trials. The average age of children at the time of measurement was extracted;
221	if the precise average age at baseline and/or end-line was not reported, the average
222	age was assumed to equal the timing of measurement (e.g., if scheduled and line

age was assumed to equal the timing of measurement (e.g., if scheduled end-line

follow-up was at 6 months, the average age was assumed to equal baseline age plus 6

months). Analyses were conducted combining sexes as it was assumed this was the

225 manner in which data would be most often reported. If the ratio of females and males

was reported, this was extracted to generate a sex-weighted WHO-GS LMS table;

227 otherwise, an equal ratio was assumed.

228

iv) Statistical analyses – application of the PMB and comparator outcomes
Extracted data were used to re-express mean HAZ and the associated 95% CI as mean
height-age with 95% CIs. The height-age mean difference (MD) (intervention minus
control) at the study end-line was determined with 95% CIs (30). This was compared to

Height-age as an alternative growth outcome

233 how results were reported in the published paper (HAZ MD); to ensure direct 234 comparability, we recalculated the HAZ MD using the same method as used for the 235 height-age MD (30). The MD between groups' changes in height-age during the 236 observation period (end-line height-age minus baseline height-age) was also 237 determined with 95% CIs using methods outlined in **Supplemental Methods** and 238 **Supplemental Table 1**, as an intermediary step to facilitate calculation of the PMB. To 239 calculate 95% CIs for the PMB, the 95% confidence bounds for the MD between groups' 240 changes in height-age were substituted in the PMB numerator in Equation 2, as the 241 numerator in *Equation 2* is the MD between the intervention and control group's change in height-age over the observation period (i.e., to calculate the upper 95% bound for the 242 243 PMB, the upper bound of the 95% CI for the MD between groups' changes in height-age 244 was substituted into the numerator of the PMB metric; the same was done to calculate 245 the lower bound). As a sensitivity analysis, we repeated this exercise using mean height 246 if it was also reported at baseline and/or end-line to compare height-age and PMB 247 estimates generated from mean height versus mean HAZ. All analyses were performed 248 in STATA software version 17 (STATA Corp LLC).

249

250 **RESULTS**

Across six age timepoints in the MDIG/BONUSKids cohort, the maximum absolute difference between mean height-age estimates generated from mean HAZ versus mean height was 1 day (Range: 0 to 1). The maximum difference between SEs generated from mean HAZ versus from a distribution of height-ages (generated from individuallevel heights), was 0.3 day (Range: 0 to 0.3) (**Table 1**). These results were similar when

Height-age as an alternative growth outcome

256	the analyses was disaggregated by sex. The distribution of individual height-age
257	estimates consistently showed slightly greater skewing (Mean skewness: 0.4 for height-
258	age; 0.05 for height; 0.01 for HAZ) and excess kurtosis (Mean kurtosis: 3.5 for height-
259	age; 3.2 for height; 3.1 for HAZ) compared to the raw height and HAZ distributions
260	(Table 2).
261	
262	Including MDIG and BONUSKids, 7 reports of 4 trials of 2 distinct nutrition-specific
262	interventions involute at in $ M $ covers included in the pilot study (Table 2). The

interventions implemented in LMICs were included in the pilot study (**Table 3**). The

interventions were the provision of 1 egg/day from 6 to 12 months of age (the Lulun and

265 Mazira trials) and maternal or infant vitamin D supplementation (the Delhi Infant Vitamin 266 D Supplementation (DIVIDS) and MDIG trials). Group/study-level mean HAZ was

available at baseline, end-line, and post-intervention follow-up (if applicable) for all

268 included studies. Group-level baseline LAZ for the DIVIDS trial was obtained from

another report (31).

270

The egg intervention introduced in the Lulun trial led to a significant increase in mean LAZ at 12 months (19), while the same intervention in the Mazira trial did not (20). Infant vitamin D supplementation in the DIVIDS trial led to a significant increase in LAZ at 6 months (21), while maternal vitamin D supplementation in the MDIG trial did not improve children's linear growth at 1 year (16). Three of the four trials had postintervention follow-ups (Lulun, DIVIDS, and MDIG), and no sustained or latent improvements in linear growth were observed (17, 18, 22).

Height-age as an alternative growth outcome

279 Inferences and directions of the intervention effects at end-line were consistent when expressed on the HAZ and height-age scales (Table 4). For example, the Mazira trial 280 281 results expressed as the LAZ or height-age MD both indicated that the intervention did 282 not significantly improve linear growth. However, neither of these effect estimates 283 conveyed the extent of linear growth improvement achieved by this intervention relative 284 to a benchmark of children's optimal growth potential. The PMB revealed that the 285 provision of 1 egg/day for 6 months in this population achieved 9.4% of the intervention 286 group's growth potential beyond growth in the control group. For the Lulun trial, the LAZ 287 and height-age MD both showed that this intervention improved growth; the PMB suggested that this intervention achieved 94% of the intervention group's optimal growth 288 289 potential. For the DIVIDS and MDIG trials, height-age was not derived at baseline as 290 the intervention began at birth, so the PMB could not be calculated (an intermediate step to enable calculation of the PMB is determining the change in height-age from 291 292 baseline to end-line). For the trials with post-intervention follow-ups, the PMBs ranged 293 from -0.28% to 5.2% (Table 4).

294

The Lulun and Mazira trial results were plotted as LAZ-for-age (**Figure 4 Panel A**) versus height-age-for-age (**Figure 4 Panel B**). In the Lulun trial, there was essentially no change in the control group's LAZ with age (from baseline to end-line), while the intervention group's LAZ increased towards 0 (Figure 4 Panel A), and the corresponding change in height-age was nearly parallel with the change in chronological age (Figure 4 Panel B). No major differences were visually apparent between the intervention and control groups in the Mazira trial on the LAZ-for-age or height-age-for-age scales.

Height-age as an alternative growth outcome

302

303	The sensitivity analysis showed that height-age estimates derived from mean
304	length/height (n=2 trials) did not notably differ from estimates calculated from mean
305	LAZ/HAZ, provided the age interval over which data was aggregated was narrow
306	(Supplemental Table 2).
307	
308	DISCUSSION
309	Childhood linear growth faltering is a pervasive public health problem in LMICs for
310	which progress towards global targets has been incomplete (32). New methods of
311	communicating the results of controlled trials and program evaluations may influence
312	public health priority-setting. In this work, height-age was used as an alternative
313	expression of group-average child linear growth, and the PMB was used to quantify the
314	extent of linear growth improvement achieved by nutrition-specific interventions tested
315	in RCTs in LMICs.
316	
317	Application of height-age and the PMB metric to assess the effect of interventions builds
318	on findings from prior work demonstrating that the analysis of changes in mean HAZ
319	with age does not enable clear determinations of group-level catch-up growth (25). Due
320	in part to the popularity of the Victora plots (HAZ-by-age curves), it is conventionally
321	assumed that stable HAZ often seen after 2 years of age (beyond the first 1000 days)
322	reflects normal average growth and that an upward trend in HAZ (towards HAZ=0) is
323	evidence of catch-up (33). However, plotting of the Lulun trial results showed that the
324	control group's stable HAZ was sub-optimal on the height-age-for-age scale.

Height-age as an alternative growth outcome

325

326 Early definitions of catch-up growth suggested that the goal of catch-up was to return 327 children to their pre-faltering growth curve (34, 35), which may have provided the basis 328 for this assumption in HAZ-tracking. However, expecting an intervention to return a 329 previously faltered population-average HAZ to the median for chronological age 330 (HAZ=0) is usually unrealistic, as this would suggest that growth proceeds at a rate 331 faster than expected for chronological and skeletal age. While this may be observed at 332 the individual level (34), linear growth faltering in LMICs is due to numerous factors, 333 including inadequate dietary intake, infections and other inflammatory stimuli, and 334 psychosocial factors (2). Public health interventions, including nutrition-specific 335 interventions such as micronutrient supplementation, are often implemented for a 336 relatively short period of time and do not address all the factors limiting linear growth. Therefore, even small increases in HAZ (or reductions in stunting) may be unlikely, 337 338 highlighting a need to temper general expectations and quantify the growth that could 339 feasibly occur in these settings (8).

340

The PMB incorporates a theory-based benchmark of optimal growth that could occur in LMIC settings, based on a current understanding of the biology of long bone growth. In developing the PMB metric, we assumed that a PMB of 100% would not be a realistic expectation for a single intervention that is not designed to resolve all of the many complex factors inhibiting children's growth in LMICs. As the PMB metric was developed and applied for the first time in this work, we were unable to define thresholds of success on the PMB scale. Even so, the PMB has potential value as it is a standardized

Height-age as an alternative growth outcome

348 measure of the extent to which optimal growth potential was achieved, permitting 349 assessment of the comparative efficacy of interventions and/or programs because it is 350 inherently normalized across ages and intervention durations. Further application of the 351 PMB metric to a wider array of interventions previously tested in LMICs is needed to 352 define the range of plausible PMB values and establish guidelines for using the PMB in 353 priority-setting.

354

A secondary benefit of the PMB is that it may serve as a plausibility check of trial results 355 356 in LMICs if a PMB of 100% is approximated or even exceeded. Although mathematically 357 possible, a PMB>100% would imply that the intervention promoted growth beyond what 358 is expected for children's skeletal age, which is unlikely to occur even when substantive, 359 permanent changes are made to children's environments (36). Given these expectations, an observed PMB of 94%, with an upper 95% CI exceeding 100%, as 360 361 calculated for the Lulun trial, should be interpreted with caution. When the Lulun trial 362 was first reported, it received considerable attention due to the impressive apparent 363 effect on linear growth (37, 38), especially given the simplicity of the intervention (19). 364 However, the findings of the Lulun trial were not confirmed in a similar trial in Malawi 365 (the Mazira study), which had a much larger sample (about 4 times greater than the 366 Lulun trial) (20). It is possible the Lulun trial findings occurred due to imperfect 367 randomization (19), and the very high PMB suggests the findings are unlikely to be 368 replicable.

369

Height-age as an alternative growth outcome

370 Findings of this study provide a toolkit for researchers to use in future applications of height-age and the PMB to RCT analysis. First, we found that in secondary use studies 371 372 (i.e., re-analysis of published results), acceptable group-average height-age estimates 373 can be derived from reported mean HAZ if mean height is not available. When IPD is 374 available, it is feasible to generate individual child-level height-age estimates from 375 individual-level height, and then calculate the population-average height-age. However, 376 individual child height-age estimates are not readily interpretable as they incorrectly 377 imply that each child should track along the median curve of the growth standard. The 378 sensitivity analysis in the pilot study showed that derived height-age estimates are 379 sensitive to the width of the age range over which data are aggregated. Therefore, 380 estimating mean height from individual-level height data collected over a narrow age 381 range and then deriving the corresponding mean height-age is currently the 382 recommended approach. These and additional recommendations are summarized in 383 Figure 5.

384

385 Bone age based on radiographic criteria is another method of estimating skeletal age; 386 however, height-age may be preferable in faltered populations as it might provide a 387 more accurate portrayal of delays in long bone growth, which contributes to child height, 388 whereas bone age is based on radiographs of smaller bones in the hand and wrist (36). 389 Height-age is also more practical in LMICs and can be used to re-express previously collected height data in trials. However, a limitation of the PMB metric is that it has 390 391 additional data requirements beyond what is needed for end-line comparisons of mean 392 HAZ, as evidenced by the incompleteness of results in the pilot study (Table 4). Also,

Height-age as an alternative growth outcome

393	this study relied on the WHO-GS LMS table for children 0 to 5 years of age to select a
394	height-age, yet growth faltering in LMICs has a prenatal onset and progresses in the
395	early postnatal period even with exclusive breastfeeding (39), such that postnatal length
396	deficits may be severe enough that the average observed length is smaller than the
397	WHO-GS median length at day 0. As well, there has been increased emphasis on
398	extending efforts for improving child growth into adolescence (i.e., beyond 5 years of
399	age) (40, 41), so height-age methods should be further developed to encompass these
400	age groups. Future work will incorporate other growth references, such as the
401	INTERGROWTH-21st standards for infants (42) and the WHO growth reference data
402	from 5 to 19 years, to extend the use of these methods from birth to adolescence.
403	
404	Height-age is an alternative growth metric that can be used in place of HAZ and may
405	offer advantages for reporting and interpreting group-average faltering and catch-up
406	patterns in RCTs. Given the entrenched reliance on mean HAZ and stunting prevalence
407	in global child health research, program evaluation, and country-level monitoring in
408	LMICs, researchers may be reluctant to adopt alternative expressions of child growth.
409	Therefore, elaboration and further applications of the height-age-based methods
410	developed in this work are needed to expand and validate their use to stimulate
411	widespread adoption.

Height-age as an alternative growth outcome

Acknowledgements: DER, DGB, KMW, KMOC, ASBD, HQ, and CYC designed research; KMW conducted research; KMW, ASBD, HQ, and CYC analyzed data; and KMW and DER wrote the paper. KMW and DER had primary responsibility for final content. All authors read and approved the final manuscript.

Data Availability: Data described in the manuscript and code for the individual participant data analysis will not be made available because this data was from a trial for which consent for public sharing of individual participant data was not sought. Study-level data described in the manuscript and code for the pilot study came from publicly available reports of trials, and can be found in the respective published report cited in this paper; the extracted dataset used in this study is also available at https://github.com/kelly-watsonn/HA1.

Author Discolsures: The authors have no conflicts of interest or financial relationships relevant to the article to disclose.

Height-age as an alternative growth outcome

References

1. Victora CG, Christian P, Vidaletti LP, Gatica-Domínguez G, Menon P, Black RE. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. Lancet. 2021;397(10282):1388-99.

2. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al.

Maternal and child undernutrition and overweight in low-income and middle-income

countries. Lancet. 2013;382(9890):427-51.

3. World Health Organization. WHO child growth standards: length/height-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization; 2006.

4. Frongillo EA, Leroy JL, Lapping K. Appropriate Use of Linear Growth Measures to Assess Impact of Interventions on Child Development and Catch-Up Growth. Adv Nutr. 2019;10(3):372-9.

5. Perumal N, Bassani DG, Roth DE. Use and Misuse of Stunting as a Measure of Child Health. J Nutr. 2018;148(3):311-5.

6. Roth DE, Krishna A, Leung M, Shi J, Bassani DG, Barros AJD. Early childhood linear growth faltering in low-income and middle-income countries as a whole-population condition: analysis of 179 Demographic and Health Surveys from 64 countries (1993-2015). Lancet Glob Health. 2017;5(12):e1249-e57.

7. Subramanian SV, Karlsson O, Kim R. Revisiting the stunting metric for monitoring and evaluating nutrition policies. Lancet Glob Health. 2022;10(2):e179-e80.

USAID. Stunting: Considerations for Use as an Indicator in Nutrition Projects.
 Arlington, VA: USAID Advancing Nutrition; 2020.

Height-age as an alternative growth outcome

9. Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, et al. Catchup growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology. 1994;135(4):1367-71.

10. Finkielstain GP, Lui JC, Baron J. Catch-up growth: cellular and molecular mechanisms. World Rev Nutr Diet. 2013;106:100-4.

11. Lui JC, Nilsson O, Baron J. Growth plate senescence and catch-up growth. Endocr Dev. 2011;21:23-9.

12. Stevens DG, Boyer MI, Bowen CVA. Transplantation of epiphyseal plate allografts between animals of different ages. J Pediatr Orthop. 1999;19 3:398-403.

13. Marino R, Hegde A, Barnes KM, Schrier L, Emons JA, Nilsson O, et al. Catch-Up Growth after Hypothyroidism Is Caused by Delayed Growth Plate Senescence. Endocrinology. 2008;149(4):1820-8.

14. Gafni RI, Weise M, Robrecht DT, Meyers JL, Barnes KM, De-Levi S, et al. Catch-Up Growth Is Associated with Delayed Senescence of the Growth Plate in Rabbits. Pediatr Res. 2001;50(5):618-23.

15. Emons JA, Boersma B, Baron J, Wit JM. Catch-up growth: testing the hypothesis of delayed growth plate senescence in humans. J Pediatr. 2005;147(6):843-6.

16. Roth DE, Morris SK, Zlotkin S, Gernand AD, Ahmed T, Shanta SS, et al. Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. N Engl J Med. 2018;379(6):535-46.

17. O'Callaghan KM, Shanta SS, Fariha F, Harrington J, Mahmud AA, Emdin AL, et al. Effect of maternal prenatal and postpartum vitamin D supplementation on offspring

Height-age as an alternative growth outcome

bone mass and muscle strength in early childhood: follow-up of a randomized controlled trial. Am J Clin Nutr. 2022;115(3):770-80.

18. Iannotti L, Chapnick M, Nicholas J, Gallegos-Riofrio C, Moreno P, Douglas K, et al. Egg intervention effect on linear growth no longer present after two years. Matern Child Nutr. 2019;16.

19. Iannotti LL, Lutter CK, Stewart CP, Gallegos Riofrío CA, Malo C, Reinhart G, et al. Eggs in Early Complementary Feeding and Child Growth: A Randomized Controlled Trial. J Pediatr. 2017;140(1).

20. Stewart CP, Caswell B, Iannotti L, Lutter C, Arnold CD, Chipatala R, et al. The effect of eggs on early child growth in rural Malawi: the Mazira Project randomized controlled trial. Am J Clin Nutr. 2019;110(4):1026-33.

21. Kumar GT, Sachdev HS, Chellani H, Rehman AM, Singh V, Arora H, et al. Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial. BMJ.

2011;342:d2975.

22. Kumar GT, Kaur M, Rehman AM, Arora H, Rajput MM, Chugh R, et al. Effects of vitamin D supplementation in infancy on growth, bone parameters, body composition and gross motor development at age 3–6 years: follow-up of a randomized controlled trial. Int J Epidemiol. 2015;44(3):894-905.

23. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr. 1990;44(1):45-60.

Height-age as an alternative growth outcome

24. WHO. Child growth standards - The WHO Anthro Software Packages and Macros STATA macro igrowup_update [Internet]. [cited 2022 Dec 12]. Available from: https://www.who.int/tools/child-growth-standards/software.

25. Mansukoski L, Qamar H, Perumal N, Aimone A, Bassani DG, Roth DE. Growth delay: an alternative measure of population health based on child height distributions. Ann Hum Biol. 2022;49(2):100-8.

26. Watson KM. HA1 [Internet]. 2024 [cited 2024 February 1]. Available from: https://github.com/kelly-watsonn/HA1.

27. Kourtis D, Magnusson ML, Smith F, Hadjipavlou A, Pope MH. Spine height and disc height changes as the effect of hyperextension using stadiometry and MRI. Iowa Orthop J. 2004;24:65-71.

28. WHO. WHO Child Growth Standards SAS igrowup package [Internet]. [cited 2023 Nov 12]. Available from: <u>https://cdn.who.int/media/docs/default-source/child-growth/child-growth-standards/software/readme-sas.pdf?sfvrsn=5308a21e_2</u>

29. World Bank Country and Lending Groups [Internet]. The World Bank Group [cited 2022 Jan 30]. Available from:

https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-countryand-lending-groups.

30. Confidence Interval for Two Independent Samples, Continuous Outcome [Internet]. Boston University School of Public Health. 2017 [cited 2022 May 2]. Available from: https://sphweb.bumc.bu.edu/otlt/mph-

modules/bs/bs704_confidence_intervals/bs704_confidence_intervals5.html.

Height-age as an alternative growth outcome

31. Filteau S, Kumar GT, Cole TJ, Sachdev HS, De Stavola BL. Steady Growth in Early Infancy Is Associated with Greater Anthropometry in Indian Children Born Low Birth Weight at Term. J Nutr. 2019;149(9):1633-41.

32. United Nations Children's Fund (UNICEF), World Health Organization (WHO), International Bank for Reconstruction and Development/The World Bank. Levels and trends in child malnutrition: UNICEF / WHO / World Bank Group Joint Child Malnutrition Estimates: Key findings of the 2023 edition. New York: UNICEF and WHO; 2023. CC BY-NC-SA 3.0 IGO.

Prentice AM, Ward KA, Goldberg GR, Jarjou LM, Moore SE, Fulford AJ, et al.
 Critical windows for nutritional interventions against stunting. Am J Clin Nutr.
 2013;97(5):911-8.

34. Prader A, Tanner JM, von HG. Catch-up growth following illness or starvation. An example of developmental canalization in man. J Pediatr. 1963;62:646-59.

35. Boersma B, Wit JM. Catch-up Growth. Endocr Rev. 1997;18(5):646-61.

36. Golden MH. Is complete catch-up possible for stunted malnourished children? Eur J Clin Nutr. 1994;48 Suppl 1:S58-70; discussion S1.

37. Lutter CK, Iannotti LL, Stewart CP. The potential of a simple egg to improve maternal and child nutrition. Matern Child Nutr. 2018;14 Suppl 3(Suppl 3):e12678.

38. The Incredible Egg [Internet]. American Egg Board [cited 2023 Nov 15]. Available from: https://www.incredibleegg.org/nutrition/articles/research-around-the-world.

39. Christian P, Lee SE, Donahue Angel M, Adair LS, Arifeen SE, Ashorn P, et al.

Risk of childhood undernutrition related to small-for-gestational age and preterm birth in low- and middle-income countries. Int J Epidemiol. 2013;42(5):1340-55.

Height-age as an alternative growth outcome

40. Saavedra JM, Prentice AM. Nutrition in school-age children: a rationale for revisiting priorities. Nutr Rev. 2023;81(7):823-43.

41. Vaivada T, Lassi ZS, Irfan O, Salam RA, Das JK, Oh C, et al. What can work and

how? An overview of evidence-based interventions and delivery strategies to support

health and human development from before conception to 20 years. Lancet.

2022;399(10337):1810-29.

42. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al.

International standards for newborn weight, length, and head circumference by

gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-

21st Project. Lancet. 2014;384(9946):857-68.

TABLE 1Height-age generated from mean length or height ('Mean Height'), mean LAZ or HAZ ('Mean HAZ'), orindividual-level lengths or heights ('Individual-level Heights'), using individual participant data from the Maternal vitamin Dfor Infant Growth (MDIG) trial and the BONe and mUScle health in Kids (BONUSKids) follow-up the of the MDIG cohort

Encounter ¹ n		Mean age, d	Height-age, d							
	,, participants	C	Mean Height ²		Individual-level Hei	ghts ²	Mean HAZ ³			
(montaio)	participanto		Mean (95% CI)	SE	Mean (95% CI)	SE	Mean (95% CI)	SE		
3	1028	94 (91, 162)	73 (72, 74)	0.5	74 (73, 76)	0.8	73 (72, 75)	0.8		
6	1037	185 (182, 262)	151 (149, 154)	1.3	154 (152, 157)	1.3	152 (149, 154)	1.3		
9	1128	277 (273, 348)	233 (230, 236)	1.5	235 (232, 239)	1.6	233 (230, 236)	1.5		
12	1165	368 (364, 427)	307 (304, 311)	1.8	310 (306, 313)	1.9	307 (304, 311)	1.8		
24	1100	733 (666, 807)	592 (586, 599)	3.3	597 (591, 603)	3.2	592 (586, 599)	3.3		
48	640	1510 (1431, 1553)	1242 (1226, 1259)	8.4	1251 (1235, 1268)	8.5	1242 (1226, 1258)	8.2		

¹3-, 6-, 9-, 12-, and 24-month encounters measured during the MDIG trial; 48-month encounter measured during the BONUSKids study. ²Length (mean or individual-level) used at the 3-, 6-, 9-, 12-, and 24-month encounters; height (mean or individual-level) used at the 48-month encounter. ³Mean LAZ used at the 3-, 6-, 9-, 12-month encounters; mean HAZ used at the 24- and 48-month encounters.

CI, confidence interval; d, days; HAZ, height-for-age z-score; IPD, individual participant data; LAZ, length-for-age z-score; SE, standard error.

TABLE 2 Statistical properties of the height, HAZ, and height-age distributions, generated using individual participant data from the Maternal vitamin D for Infant Growth (MDIG) trial and the BONe and mUScle health in Kids (BONUSKids) follow-up the of the MDIG trial cohort

Encounter ¹	L	ength c	or hei	ght² (ci	n)	LAZ or HA			IAZ ²	² Height-age ³ (months)				s)	
(months)	Mean	Med.	SD	Kurt.	Skew.	Mean	Med.	SD	Kurt.	Skew.	Mean	Med.	SD	Kurt.	Skew.
3	59.0	59.0	2.0	3.6	0.1	-0.9	-0.9	0.9	3.1	-0.2	2.5	2.4	0.7	5.4	0.7
6	64.9	65.0	2.2	3.0	0.0	-0.9	-0.8	1.0	3.0	-0.1	5.1	5.0	1.2	3.1	0.4
9	69.2	69.2	2.4	3.1	-0.1	-0.9	-0.9	1.0	3.1	-0.1	7.7	7.7	1.7	3.0	0.2
12	72.5	72.6	2.6	3.0	-0.1	-1.0	-1.0	1.0	3.1	-0.1	10.2	10.1	2.0	3.0	0.2
24	82.9	82.8	3.4	3.2	0.1	-1.4	-1.4	1.1	3.2	0.1	19.7	19.3	3.5	3.3	0.4
48	98.7	98.5	4.4	3.2	0.3	-1.2	-1.3	1.0	3.2	0.3	40.8	40.2	7.1	3.2	0.5

¹3-, 6-, 9-, 12-, and 24-month encounters measured during the MDIG trial; 48-month encounter measured during the BONUSKids study. ²Length and LAZ at the 3-, 6-, 9-, 12-, and 24-month encounters; height and HAZ at the 48-month encounter. ³Height-age generated at the individual-level, from length (3-, 6-, 9-, 12-, and 24-month encounters) or height (48-month encounter).

HAZ, height-for-age z-score; Kurt., kurtosis; LAZ, length-for-age z-score; Med., median; SD, standard deviation; Skew., skewness.

Country, year(s) of study, study name, <i>n</i> , authors	Intervention	Effect on linear growth	Authors' conclusions
	Infants provided 1 egg/day from age 6-12 months	LAZ MD: 0.63 (95% CI: 0.38, 0.88)	Egg intervention significantly increases linear growth
Ecuador, 2017, Lulun follow- up, <i>n</i> =135, Iannotti et al. (18)	Follow-up of Lulun trial cohort after 2 years	HAZ MD: 0.082 (95% CI: −0.15, 0.31)	Results from Lulun trial attenuated
Malawi, 2018-2019, Mazira Project, <i>n</i> =660, Stewart et al. (20)	Infants provided 1 egg/day from age 6-12 months	LAZ MD: 0.07 (95% CI: – 0.01, 0.15) ¹	Egg intervention did not benefit linear growth
India, 2007-2010, DIVIDS, <i>n</i> =2079, Kumar et al. (21)	Weekly infant vitamin D supplementation (1400 IU/week) from birth to 6 months	LAZ MD: 0.12 (95% CI: 0.02, 0.21) ²	Vitamin D supplementation significantly increased linear growth
India, 2012-2014, DIVIDS follow-up, <i>n</i> =912, Kumar et al (22)	Follow-up of DIVIDS trial cohort after 3-6 years	HAZ MD: 0.06 (95% CI: −0.07, 0.19) ³	Results from DIVIDS attenuated
Bangladesh, 2014-2018, MDIG, <i>n</i> =1300, Roth et al. (16)	Varying doses ⁴ of maternal prenatal and postpartum weekly vitamin D supplementation	No significant difference between groups LAZ at 1 year (p=0.25) ⁵	Maternal vitamin D supplementation does not improve infant's linear growth

TABLE 3Characteristics of trials and available follow-up studies included in the pilot study

Bangladesh, 2018-2020,	Follow-up of MDIG trial cohort	No significant difference	No comment on children's
BONUSKids, <i>n</i> =642,	at 4 years	between groups HAZ at 4	linear growth
O'Callaghan et al. (17)	at 4 years	years (p=0.81) ⁵	

¹Minimally adjusted comparison reported in Stewart et al. shown here; interpretation of effect unchanged when fully adjusted comparison considered. ²Adjusted comparison reported in Kumar et al. (DIVIDS) shown here; effect is insignificant when unadjusted comparison considered. ³Unadjusted comparison reported in Kumar et al. (DIVIDS follow-up) shown here; interpretation of effect unchanged when fully adjusted comparison considered. ⁴One group received neither prenatal or postpartum vitamin D (placebo group); three groups received prenatal supplementation only (4200 IU, 16,800 IU, or 28,000 IU per week); one group received prenatal and postpartum supplementation up to 26-weeks (28,000 IU/week). ⁵Analysis of variance (ANOVA) for multiple group comparisons used to measure effect on linear growth in Roth et al. (MDIG) and O'Callaghan et al. (BONUSKids).

BONUSKids, BONe and mUScle health in Kids; CI, confidence interval; DIVIDS, Delhi Infant Vitamin D Supplementation; HAZ, height-for-age z-score; LAZ, length-for-age z-score; MD, mean difference; MDIG, Maternal Vitamin D for Infant Growth.

-		E)	
Trial (intervention duration)	Time of	Mean difference (inte		
Trial (intervention duration)	assessment ²	LAZ or HAZ ³	Height-age, d	
MDIC1 (0.6 months)	End of trial	0.11 (-0.077, 0.30)	4 (-3, 11)	NA ⁴
MDIG ¹ (0-6 months)	Follow-up	0.06 (-0.20, 0.32)	16 (-38, 70)	5.2 (-15, 25)
DIV(IDS (0.6 months))	End of trial	0.11 (0.001, 0.22)	4 (0, 8)	NA ⁴
DIVIDS (0-6 months)	Follow-up	0.06 (-0.07, 0.19)	14 (-16, 44)	2.5 (-4.3, 9.3)
(0.40 month a)	End of trial	0.32 (-0.067, 0.71)	12 (-11, 35)	94 (50, 138)
Lulun (6-12 months)	Follow-up	-0.09 (-0.40, 0.22)	-40 (-96, 16)	-0.28 (-0.51, -0.06)
Mazira (6-12 months)	End of trial	0.02 (-0.15, 0.19)	4 (-7, 15)	9.4 (-9.4, 28)

TABLE 4 Effect of interventions quantified using conventional and height-age-based methods

¹Different primary end-line selected for this study (6 months) than the primary end-line reported in the MDIG trial (1 year). ²'Follow-up' represents measurement of children after an elapsed period of time following cessation of the trial. ³LAZ mean difference (MD) for all trials at end of trial; HAZ MD for all trials with follow-up. ⁴Height-age could not be calculated at baseline because methods were not developed in this work to address cases when the age of children approximates 0 days.

CI, confidence interval; d, days; DIVIDS, Delhi Infant Vitamin D Supplementation; HAZ, height-for-age z-score; LAZ, length-for-age z-score; MDIG, Maternal Vitamin D for Infant Growth; PMB, proportion of maximal benefit.




FIGURE 1 Workflow to determine height-age of children measured at or near two years of age. This workflow is intended to be used for studies in which a scheduled follow-up was at, or near, 2 years of age, as it addresses the 0.7 cm discontinuity in the WHO-GS median length/height values before and after 2 years (731 days) of age (due to the transition from supine length to standing height measurement). "Assume majority z-score is HAZ" and "Assume majority z-score is

LAZ" indicates the need to assume that this was the type of z-score that was calculated for a majority of children by the WHO macro for calculating z-scores. It is then assumed that either a standing height (for majority HAZ) or recumbent length (for majority LAZ) measurement is back-calculated from the z-score. This affects the subsequent adjustment made to the WHO-GS median values to ensure fair comparison between the observed height or length and reference values (WHO-GS median) when estimating height-age.

HAZ, height-for-age Z-score; LAZ, length-for-age Z-score; LMS, lambda-mu-sigma; WHO-GS, World Health Organization Growth Standard.




FIGURE 2 Schematic representation of the correspondence between the expected growth rate for baseline height-age given A) a conventional length-for-age curve and B) a plot of height-age as a function of chronological age. Assuming a hypothetical group of 1-year-old children who have experienced linear growth faltering, such that the average height-age is <1 year, were measured at the start of an intervention, panel A) shows that the expected growth rate for children's baseline height-age changes at any given age on the length-for-age scale, whereas panel B) shows that the expected growth rate on the height-age-for-age scale is a constant relationship across ages (slope = 1). WHO-GS, World Health Organization Growth Standard.

Data source: WHO. WHO Child Growth Standards STATA igrowup package [Internet]. 2022 [cited 2023 Jul 19]. Available from: https://github.com/unicef-drp/igrowup_update




FIGURE 3 Approaches to derive height-age estimates based on available data. 'Mean height' represents using mean height or length to derive height-age; 'Individual-level heights' represents using individual-level heights or lengths to derive individual-level height-ages; 'Mean HAZ' represents using mean HAZ or LAZ to derive height-age. The normal distributions are used to depict individual-level child data from the MDIG trial and BONUSKids study. ¹The steps within the

box represent the assumption that only mean height or HAZ are available for deriving height-age; the preceding steps are included to show how mean height and HAZ were generated from individual-level data.

CI, confidence interval; HAZ, height-for-age z-score; WHO-GS, World Health Organization Growth Standard.




FIGURE 4 Linear growth from the start to end of the intervention period in the Lulun and Mazira egg supplementation trials expressed conventionally using mean LAZ (Panel A) and height-age (Panel B). The grey line in panel A) represents the WHO Growth Standards (WHO-GS) median (LAZ=0). The green line in panel B) represents the WHO-GS median when expressed as height-age as a function of chronological age. LAZ, length-for-age Z-score.

Data sources:

lannotti LL, Lutter CK, Stewart CP, Gallegos Riofrío CA, Malo C, Reinhart G, et al. Eggs in Early Complementary Feeding and Child Growth: A Randomized Controlled Trial. J Pediatr. 2017;140(1).

Stewart CP, Caswell B, Iannotti L, Lutter C, Arnold CD, Chipatala R, et al. The effect of eggs on early child growth in rural Malawi: the Mazira Project randomized controlled trial. Am J Clin Nutr. 2019;110(4):1026-33.




FIGURE 5 Workflow for determining height-age based on methods developed in this work. Height and HAZ are

used in this figure to represent measured stature (height or length) of children.

LMS, lambda-mu-sigma; M, WHO-GS median height; S, WHO-GS coefficient of variation; WHO-GS, World Health Organization Growth Standard.